Source: Research Seminar 2015



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kolb. Angiogenesis in IPF and lung Cancer: a common pathway?. Research Seminar 2015

Member's Comments

No comment yet.

Related content which might interest you: Network-based approach identifies SP1 as a common node in emphysema and lung cancer Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Deciphering the link between COPD and lung cancer: Cigarette smoke-induced immunosuppression at the crossroads between cancer immune surveillance and escape Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 The role of HIF-1 pathway in non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis? Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 COPD; IPF; lung cancer in same individual: Can it be called 'AJMERITES SYNDROME? Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Lung cancer: only tobacco-smoking? Source: Annual Congress 2004 - Occupational Grand Round, an interactive session Year: 2004 Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Matriptase triggers pleiotropic functional responses in normal human lung fibroblasts (NHLF): Potential relevance in pathophysiology Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome in resected non-small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Treatment of pulmonary carcinoid: Are there new options? Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Pulmonary tuberculosis and lung cancer: A complex interaction Source: International Congress 2016 – The best clinical approach to lung diseases Year: 2016 Lung cancer in women: Is it different? Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 A requirement for IKKa in lung adenocarcinoma Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Epithelial mesenchymal transition (EMT) is present in both large and small airways of smokers Source: International Congress 2014 – Translational studies in COPD Year: 2014 Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014